Los Angeles Allergist

Los Angeles Allergist

Alan Khadavi, MD, APC
  • Home
  • Meet Dr. Khadavi
  • Conditions We Treat
  • Your First Visit
  • Insurance Accepted
  • Allergy and Asthma Info
    • Asthma Info
    • Allergic Rhinitis
    • Allergic Triggers
  • Blog
  • Media
  • Contact Us

9001 Wilshire Blvd. Suite 204
Beverly Hills, CA 90211
Phone: 310-282-8822

15450 Ventura Blvd. Suite 102
Sherman Oaks, CA 91403
Phone: 818-528-7776

December 24, 2025 by Alan Khadavi

Camlipixant: A New Hope for Patients With Refractory Chronic Cough and High Cough Frequency

Chronic cough—a persistent cough lasting more than eight weeks—is one of the most vexing respiratory problems clinicians encounter. For many patients, standard treatments fail to provide meaningful relief. When cough persists despite appropriate evaluation and therapy, it’s termed refractory chronic cough (RCC). This condition can dramatically affect quality of life, interrupt sleep, cause social embarrassment, and even lead to physical complications such as rib fractures or urinary incontinence.

Enter camlipixant, an emerging therapy that may finally fill a critical gap in treatment for patients with RCC, particularly those with high cough frequency.


What Is Camlipixant?

Camlipixant (also known as BLU-5937) is an investigational selective P2X3 receptor antagonist being developed for refractory chronic cough. The P2X3 receptor is a type of purinergic receptor found on sensory neurons in the airway. It plays a key role in cough reflex hypersensitivity: when ATP binds to P2X3 receptors in the airway, it can amplify nerve signaling and trigger coughing. By blocking P2X3 receptors, camlipixant aims to reduce this hypersensitivity and decrease cough frequency and severity.


Why Is It Important for High Cough Frequency?

One of the challenges in RCC research has been that patients vary widely in how often they cough. Many clinical studies now focus on patients with objectively measured high cough frequency (for example, ≥25 coughs per hour of awake monitoring), because this subgroup often experiences the most severe symptoms and is more likely to show consistent responses to treatment in trials. PubMed


Key Clinical Data: The SOOTHE Trial

The most pivotal clinical evidence to date comes from the phase 2b SOOTHE trial—a multicenter, randomized, double-blind, placebo-controlled study involving 310 adults with RCC lasting at least one year and a high baseline cough frequency (≥25 coughs/hour). PubMed

Here’s what researchers found:

  • Significant reduction in cough frequency:
    Patients treated with camlipixant 50 mg twice daily and 200 mg twice daily both showed a ~34% reduction in 24-hour cough frequency compared with placebo at Day 28. PubMed

  • Symptom relief and quality-of-life improvements:
    All camlipixant dose groups showed trends toward better scores on patient-reported measures, including cough severity (visual analog scale) and health-related quality of life (Leicester Cough Questionnaire).

  • Tolerability and safety:
    The drug was generally well tolerated. Taste alteration (dysgeusia) occurred in a small percentage (about 5–6%) of patients in active treatment arms, and was usually mild to moderate. There were no serious treatment-related adverse events reported. PubMed

These results are especially compelling because many earlier trials of P2X3 antagonists were plagued by side effects like taste disturbance or failed to show consistent cough reduction. Camlipixant appears to strike a better balance between efficacy and tolerability, especially in patients with a high burden of coughing.


What About Patients With Lower Cough Frequency?

Earlier phase 2a data (the RELIEF trial) suggested that camlipixant’s benefits may be most pronounced in patients with higher baseline cough frequency. While the overall population didn’t meet the primary endpoint in RELIEF, subgroup analyses showed significant reductions in awake cough frequency in those with higher baseline cough counts (e.g., ≥20 or ≥32.4 coughs/hour). This supports the idea that baseline cough severity matters in predicting who is most likely to benefit. AJMC


The Future: Phase 3 and Beyond

The promising phase 2b findings have paved the way for larger phase 3 trials, such as CALM-1 and CALM-2, designed to evaluate longer-term efficacy and safety over months rather than weeks. These studies will be crucial in confirming camlipixant’s place in clinical practice and could support future regulatory approvals.


Why This Matters

Refractory chronic cough is more than a nuisance—it’s a debilitating condition that affects thousands of patients worldwide and currently has no broadly approved pharmacologic therapies with robust benefits for most sufferers. Emerging treatments like camlipixant represent a targeted approach to the underlying sensory dysfunction that drives persistent coughing, rather than simply suppressing cough reflexes non-specifically. NIHR Innovation Observatory

If ongoing research continues to demonstrate meaningful reductions in cough frequency with good tolerability, camlipixant could become a game-changer for people with high-frequency refractory cough who have exhausted conventional therapies.


Takeaway

Camlipixant’s P2X3 antagonism offers real promise for patients with refractory chronic cough—especially those with high cough frequency. With significant reductions in objective cough counts and meaningful improvements in patient-reported outcomes, this novel therapy could represent a major advance in treating a condition long underserved by effective medications. Continued phase 3 results will be critical in determining its future clinical role.

Gefapixant for Chronic Cough by Merck

Filed Under: Blog

alan-khadavi
Dr. Alan Khadavi
Allergy & Asthma Specialist

Latest Posts

November 17, 2026

Low Dose Naltrexone for MCAS: Benefits, Risks, and Evidence

LDN for MCAS

November 13, 2026

Cardamom Allergy: Symptoms, Diagnosis, and What to Avoid

cardamom allergy

October 28, 2026

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

Dr. Alan Khadavi Recognized as Top Allergist in Southern California

October 26, 2026

Which Biologic Works Best for Nasal Polyps?

best biologic for nasal polyps

October 19, 2026

Xolair vs. Omlyclo: Cost, Effectiveness, Insurance & Switching

Xolair vs Omlyclo: Cost, Effectiveness, Insurance & Switching

October 8, 2026

Tapioca Allergy: Can Cassava Cause an Allergic Reaction?

tapioca allergy

October 8, 2026

Rhapsido for Symptomatic Dermographism: An Allergist Explains the New FDA-Approved Treatment

Rhapsido for symptomatic dermographism

October 6, 2026

Most Effective Treatments for Severe Atopic Dermatitis: New Rankings

`most-effective-treatments-severe-atopic-dermatitis

October 6, 2026

Should Airlines Be Required to Carry Epinephrine? An Allergist Explains

airline epinephrine requirement

October 2, 2026

Ketotifen for MCAS: Uses, Benefits, Side Effects, and U.S. Availability

ketotifen for MCAS

Read More Posts...

Follow Us…

© 2026 Allergy Los Angeles. All Rights Reserved · Log in · Return to top of page